Hutchison Medipharma Ltd. (HMP), of Shanghai,, a unit of Hutchison China Meditech Ltd., said it completed enrollment in a phase II study of fruquintinib (HMPL-013) in non-small-cell lung cancer patients in China. The double-blind, placebo-controlled, proof-of-concept study is investigating the efficacy and safety of fruquintinib, HMP's investigational small-molecule inhibitor of vascular endothelial growth factor receptors.